BACE2 and Alzheimer disease: It was developed as an oral BACE inhibitor, and it showed an IC50 of 30 nM in the preclinical studies with minor selectivity over BACE2.174 It was evaluated in combination with an anti-Aβ antibody (gantenerumab) in some studies that involved AD transgenic mouse models, and it was found to reduce the amyloid plaques with slowing down the disease progression.174 However, the hepatotoxicity induced by RG712 prevented the completion of any further related clinical trials conducted by Roch.175